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Abstract
Mature HIV-1 viral particles assemble as a fullerene configuration comprising p24 capsid hexamers, pentamers and dimers.
In this paper, we report the X-ray crystal structures of the p24 protein from natural HIV-1 strain (BMJ4) in complex with Fab
A10F9, which recognizes a conserved epitope in the C-terminal domain of the BMJ4 p24 protein. Our structures reveal a
novel shoulder-to-shoulder p24 dimerization mode that is mediated by an S-S bridge at C177. Consistent with these
structures, the shoulder-to-shoulder dimer that was obtained from the BMJ4 strain was also observed in p24 proteins from
other strains by the introduction of a cysteine residue at position 177. The potential biological significance was further
validated by the introduction of a C177A mutation in the BMJ4 strain, which then displays a low infectivity. Our data suggest
that this novel shoulder-to-shoulder dimer interface trapped by this unique S-S bridge could represent a physiologically
relevant mode of HIV-1 capsid assembly during virus maturation, although Cys residue itself may not be critical for HIV-I
replication.
Citation: Gu Y, Cao F, Wang L, Hou W, Zhang J, et al. (2013) Structure of a Novel Shoulder-to-Shoulder p24 Dimer in Complex with the Broad-Spectrum Antibody
A10F9 and Its Implication in Capsid Assembly. PLoS ONE 8(4): e61314. doi:10.1371/journal.pone.0061314
Editor: Yue Wang, National Institute for Viral Disease Control and Prevention, CDC, China
Received December 6, 2012; Accepted March 6, 2013; Published April 19, 2013
Copyright:  2013 Gu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Natural Science Foundation (Grant no. 81172895, 81172885), the National Natural Science Foundation for
Distinguished Young Scholars (Grant no. 30925030), the Project 111 of the Ministry of Education (Grant no. B06016), the Science and Technology Major Project of
Fujian Province (Grant no. 2010Y4008, 2011J06015) and International Science and Technology Collaborative Program (Grant no. 2010DFB30100, 2011DFG33050),
People’s Republic of China. Y.A.Y. acknowledges research grant support from the LHK Foundation (Grant no. R-154-000-450-720). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nsxia@xmu.edu.cn (NX); dbsyya@nus.edu.sg (YAY); shaowei@xmu.edu.cn (SL)
Introduction
The mature HIV-1 capsid is a fullerene cone comprising
approximately 250 hexamers and 12 pentamers of the viral CA
protein (p24), with seven pentamers located at the broad end and
five pentamers located at the narrow end [1–4]. The assembly of
the adjacent hexamers is mediated by the dimerization interface,
which is formed by the p24 C-terminal domain (CTD) [5–9].
Mature HIV-1 forms hexagonal arrays of hexameric rings [10],
which are composed of the p24 N-terminal domain (NTD), with
each ring connected to its six nearest neighbors via the CTD of
p24 through a CTD-CTD dimerization interface [11–13]. The
flexible nature of the p24 NTD and CTD affects the relative
positions of the NTD and CTD within the hexagonal arrays of
hexameric rings, which effectively changes the tilt of the
dimerization interface relative to the hexamer plane [10].
The HIV-1 p24 protein has been proposed to form a dimer in
solution under certain conditions that promote capsid assembly
[4]. Both full-length p24 and p24-CTD contain a rapidly
equilibrating mixture of monomers and dimers. Notably, the
dimeric affinity of p24-CTD displays 2 fold stronger than that of
full-length [14]. HIV-1 p24 CTD domains from different
constructs have been crystallized into several distinct dimerization
interfaces: the CTD domain with full affinity displays a side-by-
side conformation that is primarily stabilized by helix 9 (pdb code
1a43) [15], the CTD domain with a shorter construct displays a
similar side-by-side dimer with a tilted dyad axis (2a8o) [6], a
single amino acid residue deletion introduced in the helix 8/9
linker promotes a ‘‘domain-swapping’’ dimerization mode (2ont)
[14], and an HIV-1 inhibitor bound to p24 CTD induces an
‘‘inert’’ CTD-CTD dimer that is incapable of extending the capsid
lattice [16]. A recent pseudo-molecular hexagonal lattice structure
of the full-length HIV-1 p24 protein, which was derived from a 9
A˚ resolution electron cryocrystallography map, strongly suggests
that the mature HIV-1 capsid lattice is mediated by intermolecular
side-to-side CTD-CTD dimerization via helix 9, although the
dyad axis is different from the one observed in the side-to-side
dimer structure determined from the isolated HIV-1 p24 CTD
[6,13].
Crystallization of the full-length HIV-1 p24 protein is a difficult
task because of the intrinsic flexibility of the linker region between
the NTD and CTD, the weak interactions within hexamers and
the tendency to form capsid-like particles [4,11,12]. To overcome
this technical difficulty, many approaches have been employed,
including disulfide cross-linking by Cys mutations and dimeriza-
tion promotion by deletion mutations. These efforts have yielded
CA hexamer, CA pentamer and ‘‘domain-swapping’’ dimer
structures [14]. Although these structures have provided crucial
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structural information on the process leading to HIV-1 capsid
assembly, the mutant structures may not represent the authentic
oligomer status of the HIV-1 p24 protein in the native
environment.
To determine the structure of the full-length HIV-1 capsid p24
dimer with high dimerization affinity and without the introduction
of mutations, we systematically expressed a dozen full-length p24
capsid proteins from different HIV-1 strains. We found that p24
from the BMJ4 strain forms a dimer in solution and in viruses that
bud from infected cells. In this paper, we describe crystal structures
of the HIV-1 capsid p24 dimer from the BMJ4 strain in complex
with the Fab fragment of the broad-spectrum antibody A10F9
with different space groups. Our structures of these complexes
demonstrate that A10F9 recognizes a continuous epitope located
at a-helix 10 (residues 196 to residues 207) in the C-terminal
domain of the BMJ4 p24 capsid protein. To our surprise, the
BMJ4 p24 capsid protein formed a novel shoulder-to-shoulder
dimer interface, which was cross-linked by an S-S bridge that is
contributed by Cys177 in both molecules. This novel shoulder-to-
shoulder dimer interface was validated by mutating the cysteine at
position 177 of p24 proteins from other HIV strains. Consistent
with the structural observations, the BMJ4 p24 C177A mutant
remained as monomers in solution, and the BMJ4 HIV-1 strain
harboring a C177A mutation displayed a low infectivity. Our data
suggest that the shoulder-to-shoulder dimer interface mediated by
residue 177 could represent a physiologically relevant mode of
HIV-1 capsid assembly during virus maturation, although Cys
residue itself may not be critical for HIV-1 replication.
Results
p24 Dimer Screening and Complex Formation
To identify native HIV-1 p24 capsid proteins capable of
forming dimers in solution, we systematically screened and
expressed a dozen p24 proteins from different HIV-1 strains.
Among these, p24 capsid proteins from the BMJ4 strain displayed
a stable dimer in solution, and p24 capsid proteins from other
HIV-1 strains displayed the monomeric form in solution.
Sequence comparison analysis revealed a unique Cys at position
177 of the BMJ4 p24 capsid protein, suggesting that Cys177 could
form a disulfide bond to create a stable dimer (Fig. 1A).
To solve the crystal structure of the BMJ4 p24 capsid protein,
we screened many p24 monoclonal antibodies that are available in
our laboratory. Among these antibodies, the broad spectrum p24
antibody A10F9 displays high binding affinity, specifically targets
the BMJ4 p24 CTD domain and demonstrates high binding
affinity to live BMJ4 HIV-1 viruses budding from infected cells
(Fig. S1). We then prepared and purified the Fab fragment of the
A10F9 antibody and made a pure, stable p24 dimer in complex
with the A10F9 Fab fragment by using a gel filtration purification
approach (Fig. S2).
Overall Structure of the Complex
Next, we successfully obtained several good crystals of the BMJ4
p24 protein in complex with the A10F9 fragment, after screening
more than 100 crystals. These crystals diffract up to 3.2 A˚, 3.2 A˚
and 3.7 A˚ resolution, which belong to the space groups P212121,
P21 and C2221, respectively. The structure of the complex was
determined by molecular replacement using the Fab 13B5
fragment (PDBID: 1E6J) as the search model, and the crystallo-
graphic statistics are listed in Table 1. The structures of the
complexes determined from the three different space groups
revealed the same p24 and Fab structures; therefore, only the
structure determined from the P212121 space group at 3.2 A˚ was
used for further structural analysis.
In our structure that was crystallized in the P212121 space
group, there are two copies of noncrystallographically (NCS)
related Fab fragments bound to one p24 capsid dimer in one
asymmetric unit (Fig. 1B). In our structure, the A10F9 Fab
fragment, which was well resolved in our electron density map,
displays a canonical sandwich Ig fold. In our structure, the p24
CTD is well resolved, as determined by an excellent density map,
whereas the p24 NTD is not resolvable because of a poor density
map. Similar to published p24 structures, the p24 CTD monomer
maintains the global fold comprising a short 310 helix followed by
an extended b-strand and four a-helices. As expected, the
interaction surface between p24 and the A10F9 fragment is
located adjacent to a continuous epitope in a-helix 10 of the p24
CTD (Fig. 1B and Fig. 2A). Surprisingly, the BMJ4 p24 CTD
dimer displays a novel shoulder-to-shoulder dimer interface, which
is mediated by the covalent bond contributed from Cys177. Unlike
the published p24 CTD dimer, few hydrogen bonds or salt bridges
are involved in BMJ4 p24 capsid protein dimerization (Figs. 1B,
3A).
Interactions between p24 and the A10F9 Fab Fragment
In our structure of the complex, the A10F9 Fab fragment
recognizes a continuous epitope that resides in a-helix 10 of the
p24 CTD via the hydrophobic loops within the variable regions of
A10F9. The interaction interface buries a total of 1,140 A˚2 of the
surface area. The close interactions between p24 and A10F9 are
grouped into a collection of aromatic p-stacks at the end of a-helix
10 and numerous hydrogen bonds along one face of a-helix 10.
Both the heavy and light chains of A10F9 contribute to p24 CTD
recognition (Figs. 2A, 2C). Notably, p24 Pro207 is buried within
an aromatic cage formed by Trp92 and Tyr32 from the light chain
and Tyr105 from the heavy chain (Fig. 2C). Because Pro207 is
located at the end of a-helix 10, making a sharp turn leading to a-
helix 11, the extensive p–p interactions contributed by the
aromatic cage may serve a critical role by anchoring the p24
CTD. The molecular interactions between the p24 CTD and the
A10F9 Fab fragment are further supplemented through intermo-
lecular hydrogen bonds between the main chains of Leu205 and
Ala204 from p24 and the Thr94 and Arg96 side chains of the Fab
light chain and the hydrogen bonds between the p24 Arg203,
Thr200, and Asp197 side chains and the Fab heavy chain Ser52,
Ser56, and Glu100 side chains (Fig. 2C).
These structural observations are consistent with our in vitro
binding assay of numerous p24 mutants using the A10F9 antibody.
The introduction of an Ala mutation at Arg203 disrupts the
hydrogen bonds formed between Glu100 of A10F9 and Arg203 of
p24, the introduction of an Ala mutation at T200 disrupts the
hydrogen bonds formed between Ser52 of A10F9 and Thr200 of
p24, and the introduction of an Ala mutation at Asp197 disrupts
the hydrogen bonds formed between Ser56 of A10F9 and Asp197
of p24, which significantly reduces the binding affinity (quantified
as EC50) between p24 and A10F9 (Fig. 2D). In contrast, the
introduction of an Ala mutation at a site that is distant from the
binding surface, such as N195A, has no impact on the binding
affinity of A10F9 for p24 (Fig. 2D). Notably, the introduction of an
Ala mutation at Leu205 significantly reduces the binding affinity,
suggesting that the hydrophobic interaction between Leu205 of
p24 and Tyr32 of A10F9 is crucial for binding (Figs. 2C, D).
Shoulder-to-shoulder HIV-1 p24 Dimer
Our p24-A10F9 complex structure demonstrates that the BMJ4
p24 capsid protein forms a dimer in the crystal structure (Fig. 1B),
Crystal Structure of HIV-1 Capsid p24 Dimers
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which is supported by the observation that the BMJ4 p24 capsid
protein forms a dimer in solution, and this result was validated by
native gel and analytical ultracentrifugation experiments (Figs. 3A,
B). By contrast, the p24 molecules from other HIV-1 isolates
contain a rapidly equilibrating mixture of monomers and dimers
in solution at our condition (Fig. 3B). To further investigate
whether BMJ4 p24 capsid protein dimerization occurs in vivo, the
BMJ4 p24 capsid protein was isolated from HIV-1 viruses that bud
from infected cells. Strikingly, the BMJ4 p24 capsid protein forms
a dimer even in budding HIV-1 viruses, which suggests that the
BMJ4 p24 dimerization that we observed in solution might be
physiologically relevant (Figs. 3C, D). Consistent with this idea, the
BMJ4 p24 dimer structure that was determined by three different
space groups reveals an identical novel shoulder-to-shoulder dimer
interface. Within our structure of the complex, the p24 CTD
dimer portion (residues 149–221) was traced without ambiguity,
whereas the p24 NTD portion was impossible to trace because of
the low-quality density map. Nevertheless, our structure demon-
strates that the p24 dimer interface is mediated by the p24 CTD,
whereas the p24 NTD is not involved in dimerization.
Figure 1. Domain architecture, sequence alignment and overall structure of the HIV-1 p24 capsid protein. (A) Sequence alignment and
secondary structure of the HIV-1 p24 capsid protein C-terminal domain (CTD). The aligned sequences are in the following order: BMJ4, P3P24, BNL,
B89.6, AE90, BRF, B22, BSG, B90, B92, B93, B94, B249 and GNG. The p24 secondary structure diagram is shown on the top. The a-helices are indicated
as bricks. The critical 177 residue is boxed in red. (B) Ribbon (left panel) and surface (right panel) representation of the p24 CTD structure in complex
with the A10F9 Fab fragment. The p24 CTDs are in blue and cyan; the Fab light chains are in yellow; and the Fab heavy chains are in magenta. The
critical Cys177 residues are labeled in red.
doi:10.1371/journal.pone.0061314.g001
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Detailed structural analysis demonstrates that the p24 CTD
dimer interface is mediated by a single disulfide bond, which is
provided by Cys177 in two monomers (Fig. 4A). Similar to
previously reported p24 CTD dimers, BMJ4 p24 is dimerized by
the parallel packing of a-helix 9 across the dimer interface.
However, few hydrogen bonds and/or salt bridges are involved in
dimerization in our BMJ4 p24 dimer structure (Fig. 4B). The
reported p–p interaction that is contributed by the conserved
Trp184, which is found along the dimer interface, is not observed
in our BMJ4 p24 dimer structure. In our structure, the distance
between the Trp184 residues of two monomers is 7 A˚, and they
are not p-stacked on each other (Fig. 4B). In our BMJ4 p24 dimer
structure, a-helix 9 is well folded to form a standard a-helix,
whereas Cys177 is located in the loop linking a-helix 9 and a-helix
10, which is ,4 A˚ away from Trp184. Therefore, our shoulder-to-
shoulder dimer displays a novel dimer interface compared with
previously published p24 dimer interfaces (Fig. 4A, B).
The loose interaction between p24 monomers revealed by our
BMJ4 p24 dimer structure is consistent with the low dimerization
affinities displayed by both the p24 and p24 CTD dimers in
solution. In contrast, the large solvent-accessible surface areas
observed in other p24 dimer structures, such as the domain-
swapping dimer interface, are probably due to dimer interface
rearrangement that is driven by packing force.
We speculate that the p24 dimer interface could only be trapped
by HIV-1 capsid assembly force due to the weak interactions
between p24 monomers. The disulfide bond contributed by BMJ4
p24 Cys177 provides a unique opportunity to lock the p24 dimer
interface before HIV-1 capsid assembly. Indeed, a BMJ4 p24
capsid mutant protein bearing the C177A mutation displays a
monomeric form in solution (Fig. 4C, 4D) and budding HIV-1
viruses (Fig. 3C).
To investigate whether this shoulder-to-shoulder dimer interface
mediated by residue 177 is a universal structural feature of other
HIV-1 strains, we introduced a Cys at residue 177 in the p24
capsid protein from the P3P24 strain. As expected, the P3P24 p24
capsid protein formed a dimer in solution after the introduction of
a disulfide bond at residue 177 (Figs. 4C, 4E). Therefore, it is
conceivable that p24 capsid proteins from other HIV-1 strains
dimerize at residue 177, and the introduction of a Cys at position
177 will trigger stable p24 dimer formation in solution.
To further investigate whether the stable dimer interface
mediated by C177 is crucial for the HIV-1 BMJ4 strain function
in vivo, a BMJ4 C177A mutant strain was created to infect human
cells in culture to evaluate the infectivity. Strikingly, the
introduction of a C177A mutation in the HIV-1 BMJ4 strain
not only disrupted BMJ4 p24 capsid dimerization in the budding
virus (Fig. 3C) but also compromised the amplification rate and
infectivity of the HIV-1 BMJ4 strain in cultured cells (Fig. 4F).
Therefore, the novel shoulder-to-shoulder p24 dimer interface
mediated by residue 177 that was identified in the BMJ4 p24
dimer could represent a physiologically relevant mode of HIV-1
capsid assembly during virus maturation, although Cys residue
itself may not be critical for HIV-I replication.
Discussion
Comparison with Other Antibodies Recognizing HIV-1
p24 CTD
Monoclonal antibodies (mAbs) with a broad capacity to
neutralize the infectivity of diverse HIV-1 strains are being
pursued as protective passive vaccines against HIV-1. The
envelope glycoprotein spike (Env) of HIV-1 is one of the primary
target for vaccine development, but the HIV-1 capsid has also
been considered as a targets for vaccine development [10,17–19].
In the literature, several Fab fragment crystal structures of mAbs
raised against HIV-1 p24 have been reported; some Fab fragments
specifically recognize the p24 NTD, whereas others specifically
recognize the p24 CTD [20–22].
We generated several dozen monoclonal antibodies that are
directed against recombinant HIV-1 p24 proteins and have high
binding affinities, thus providing a monoclonal antibody pool with
which to identify the unique characteristics of antibodies specific
for p24 proteins from different HIV-1 strains. We have successfully
identified that the monoclonal antibody A10F9 displays a broad
substrate spectrum and high binding affinity for BMJ4 p24 in vitro
and ex vivo (Figure S4). Our protein-protein interaction assay,
which was followed by structural mapping, demonstrates that
A10F9 specifically recognizes the BMJ4 p24 CTD (Fig. S3). Our
detailed structural analysis of the complex structure reveals that
the Fab heavy chain Ser52, Ser56 and Glu100 residues and the
Fab light chain Thr94 and Arg96 residues form hydrogen bonds
with residues at one surface of p24 a10, whereas the Fab light
chain Trp92 and Tyr32 residues and Fab heavy chain Tyr105
residue provide an aromatic cage that recognizes the invariable
Pro207 residue of p24 (Fig. 2C).
Next, we tested whether these residues involved in p24 CTD
recognition in the A10F9 Fab structure are conserved in other
monoclonal antibody structures. We performed a structural
comparison of our Fab fragment structure with the crystal
structure of the Fab13B5 fragment recognizing the C-terminal
domain of an intact p24 mutant at 3 A˚ resolution (PDBID: 1E6J)
[20]. Notably, mAb 13B5 recognizes a nearly continuous epitope
Table 1. Data collection, phasing and refinement statistics for
BMJ4 p24 capsid-A10F9 Fab complex.
Data collection
Cell parameters (A˚) a = 83.11, b = 124.06, c = 150.83
Space group P212121
Resolution range (A˚) 50.0-3.2 (3.26–3.20)
Wavelength (A˚) 0.9793
Redundancy 14.0 (14.0)
Completeness (%) 99.9 (100)
Overall (I/sI) 25.2 (6.8)
Rsym (%)a 12.7 (44.8)
Refinement
Resolution range (A˚) 50–3.2
Number of Reflections 24,996
R work (%) 21.1
R free (%) 29.2
No. atoms Protein 7,806
B-factors (A˚2) Protein 71.1
RMSD bond lengths (A˚) 0.015
RMSD bond angles (u) 1.7
Ramachandran Plot
Most favored region (%) 83.2
Disallowed regions (%) 0.5
aValues for the highest-resolution shell are in parentheses.
doi:10.1371/journal.pone.0061314.t001
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within a loop (residues 205–213) between a-helix 10 and a-helix
11 in the p24 CTD with a relatively small contact area, which is
mostly contributed by heavy chain residues (Fig. 2B) [21]. In
contrast, our mAb A10F9 antibody recognizes a continuous
epitope along one surface of a-helix 10 (residues 196–207) in the
p24 CTD with extensive hydrogen bonds that are contributed
from residues in the heavy and light chains (Figs. 2A, 2C).
Strikingly, the invariable Pro207 residue seems to be critical for
Fab recognition in the 13B5-p24 and A10F9-p24 structures. In the
13B5 structure, the Pro207 residue is recognized by two Tyr
residues in the heavy chain by van der Waals interactions (Fig. 2B),
whereas in the A10F9 structure, Pro207 is recognized by Trp92
Figure 2. Detailed structural features of p24 CTD recognition by Fab. (A) Ribbon representation of an overall view of p24 CTD recognition by
the A10F9 Fab fragment. The p24 CTD is in blue, the Fab light chain is in yellow, and the Fab heavy chain is in magenta. The p24 a-helix (a10)
recognized by the Fab fragment is in red. The residues involved in protein-protein interactions are shown in stick mode. (B) Ribbon representation of
an overall view of p24 CTD recognition by Fab13B5 (PDBID: 1E6J). The p24 CTD is in blue, the Fab light chain is in yellow, and the Fab heavy chain is
in magenta. The short loop between a10 and a11 of p24, which is recognized by Fab, is in red. The Tyr residues that are involved in protein-protein
interactions are shown in stick mode. (C) Ribbon representation of a detailed view of p24 CTD recognition by the A10F9 Fab fragment. The residues
involved in protein-protein interactions are indicated and shown in stick mode. (D) EC50 calculation of BMJ4 p24 and its mutants after precipitation
with the A10F9 mAb. The OD450 nm vs. the A10F9 ELISA concentration curves were fitted to the half point of the effective concentration (EC50), and
the values are shown in brackets.
doi:10.1371/journal.pone.0061314.g002
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and Tyr32 from the light chains and Tyr105 from the heavy chain
through p–p interactions (Figs. 2A, 2C). Interestingly, the Pro207
conformation in p24 was reported to be dramatically changed
after Fab binding [20]. Therefore, it is conceivable that Pro207
could be a vaccine development target.
Comparison with other HIV-1 p24 Dimer Interfaces
The HIV-1 p24 dimer interface determines the relative
positions between the two adjacent capsid building blocks and,
eventually, capsid assembly. Therefore, high-resolution structures
of the p24 dimer should provide important information to
understand the molecular insights into HIV-1 capsid assembly.
However, many p24 dimer structures with significant deviations
are reported in the literature, and no conclusively authentic dimer
interface has been validated.
In one case, full-length p24 was reported to form a head-to-tail
dimer via extensive intermolecular interactions between the NTD
and CTD [20,23], which, however, is not supported by hydrogen-
deuterium exchange and chemical cross-linking experiments [24].
Figure 3. The BMJ4 p24 protein forms a dimer in solution and in budding viruses. (A) Recombinant p24 proteins encoded by different HIV
CA genes representing various subtypes were subjected to non-reducing SDS-PAGE. Only BMJ4 p24 displays a dimeric form, as determined by non-
reducing SDS-PAGE. (B) The c(M) profiles resulting from sedimentation velocity (SV) were used to determine the apparent MW of the various p24
proteins in solution. The BMJ4 p24 protein displays a dimeric form, which is consistent with gel electrophoresis analysis. (C) p24 proteins extracted
from an HIV lysate that was infected by infectious clones, including NL 4–3, MJ4 and the MJ4 C177A mutant, were subjected to non-reducing SDS-
PAGE. Dimerization associated with the disulfide bond contributed by residue 177 was validated in a native HIV virion. The p24 dimers are indicated
by red stars. (D) p24 proteins extracted from HIV lysates infected by infectious clones, including NL 4–3, MJ4 and the MJ4 C177A mutant, were
subjected to reducing SDS-PAGE. The p24 dimers formed by disulfide bonds were dissociated under reducing conditions.
doi:10.1371/journal.pone.0061314.g003
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Figure 4. The HIV-1 p24 capsid protein dimer interface is mediated by residue 177. (A) Ribbon representation of the BMJ4 p24 CTD dimer.
BMJ4 p24 CTD dimers are in blue and cyan. The critical Cys177 residues are shown in stick mode in red, the conserved Trp184 residues are shown in
stick mode in magenta, and the Met 185 residues are shown in stick mode in yellow. (B) A 90u rotation of (A) along the X-axis. (C) Analytic gel filtration
is used to determine the apparent MW of BMJ4 p24 and its C177A mutant in solution. Disulfide bond disruption disrupts the stable dimer formation
in solution, which is consistent with the gel electrophoresis analysis. (D) Analytic gel filtration is used to determine the apparent MW of P3 p24 and its
A177C mutant in solution. The introduction of the disulfide bond triggers stable dimer formation in solution, which is consistent with gel
electrophoresis analysis. (E) Validation of the critical role of Cys177 in stable dimer formation in solution. Recombinant p24 proteins encoded by BMJ4
and P3P24 were first treated under non-reducing (N) and reducing conditions (R) and subjected to SDS-PAGE. Monomers and dimers are indicated by
the arrows. Disruption of the disulfide bond through the C177A mutation in the BMJ4 p24 protein disrupts stable dimer formation in solution, and
the introduction of a disulfide bond through the A177C mutation in the P3 p24 protein triggers stable dimer formation in solution. (F) Infection
activity of the HIV MJ4 strain and its p24 C177A mutant strain. The cells were infected with two HIV titers (quantified by p24-based ELISA) in the
presence or absence of 15 mg/ml DEAE/dextran. The average and standard error of five replicates of ELISpot counts are shown. P-value analysis was
applied to statistic evaluation for infectivity difference.
doi:10.1371/journal.pone.0061314.g004
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Thus, no functional evidence supports such a dimerization
interface.
In the second case, the p24 CTD (residues 151–231) was
reported to form a dimer in a head-to-head manner via parallel
packing of a-helix 9 across the dimer interface [6] (PDBID: 1A8O)
(Fig. 5A). However, constructs that lack the most conserved MHR
segment display low dimerization affinity compared with full-
length p24 [25]. In contrast, the p24 CTD (residues 146–231),
which comprises the MHR segment, displays comparable dimer-
ization affinity as the full-length p24 (PDBID: 1BAJ) (Fig. 5B)
[15,26]. Although both of these p24 CTD constructs are
dimerized in a head-to-head manner, the p24 CTD (residues
146–231) construct displays a more packed dimerization interface,
with extensive hydrogen bonds and salt bridges (Fig. 5B) [6,15].
Consistent with the head-to-head CTD dimerization interface that
is observed in crystal structures, mutation of Trp184 or Met185 to
Ala along this dimer interface abolishes dimerization in solution
[6] and blocks capsid assembly in vitro and HIV-1 replication in
culture [27].
In the third case, the p24 CTD (residues 144–231) dimer was
determined by NMR in solution (Fig. 5C) [13]. Analogous to X-
ray structures, the p24 CTD forms a dimer in a head-to-head
manner, with extensive hydrophobic interactions between residues
at the N-terminus of the CTD and residues residing in a-helix 9.
Although the p24 CTD used a similar group of residues, such as
Trp184 and Met185, for dimerization, the relative orientation
between the two monomers is different. The p24 CTD dimer
solved by NMR displays a V-shape-like architecture (Fig. 5C)
(PDBID: 2KOD), which is partly supported by the cryo-EM study
of the HIV-1 CA tubular structure at 16 A˚ resolution and an
electron density map derived from flattened 2D sheets formed by
full-length p24 [11].
In our structure, p24 CTD dimerization is mediated by the
same a-helix 9 in a novel shoulder-to-shoulder manner (Figs. 4A,
B). Although the p24 CTD monomer structure is almost identical
to those reported in crystals and solution (r.m.s.d 1.3 A˚,2.1 A˚),
our p24 dimer structure displays a significantly different dimer
interface compared with those from the reported dimer structures
(Fig. 5). Our BMJ4 p24 dimer structure is closer to the p24 CTD
dimer structure (residues 151–231) (PDBID: 1A8O), with an
approximately 15-degree rotation along the dimerization dyad,
which is mediated by a-helix 9 (Fig. 5A, 5D) [6,15]. Therefore, the
Figure 5. Comparison between the BMJ p24 CTD dimer structure and previously reported CTD dimer structures from X-ray
crystallography and NMR. (A, B, C) Backbone atomic superimpositions of the BMJ4 p24 structure (green) and the crystal structures 1A8O (cyan),
1BAJ (yellow) and 2KOD (wheat). Best-fit superimposition is performed for one monomer unit to highlight the difference in subunit orientations in
the dimers. The critical 177 residues are marked in the sphere in red. (D,E,F) Rotation of (A, B, C) by 90u around the X-axis.
doi:10.1371/journal.pone.0061314.g005
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previous dimerization residues, including W184 and M185, are
further away from their corresponding residues in our BMJ4 p24
dimer structure. Few hydrogen bonds and hydrophobic interac-
tions are observed along this dimerization interface (Fig. 4B). In
our structure, Cys177 plays the determining role for dimerization
by providing disulfide bonds to link the two monomers together.
Notably, Cys177 is located in the loop that links to the beginning
of a-helix 9, which is ,4 A˚ away from Trp184 (Fig. 4A).
Consistent with the importance of the new dimerization interface
observed in the BMJ4 p24 dimer, the disruption of this disulfide
bond by introduction of the C177A mutation abolishes p24
dimerization in solution and compromises the infection activity of
the HIV-1 BMJ4 strain in cultured cells (Fig. 4F).
The comparisons of the three p24-CTD dimers solved by NMR
and X-ray crystallography strongly suggest that the p24 CTD is
dimerized via a-helix 9 in a CTD-CTD manner. However, the
relative orientation of the dimerization interface varies greatly. No
evidence has been obtained to support and/or exclude any of the
possible models mentioned above. In addition, full-length p24
displays low dimerization affinity in solution, as determined by
NMR experiments [13] and our native gels (Fig. 3A). In contrast,
the isolated p24 CTD displays elevated dimerization affinity.
Therefore, the isolated p24 CTD dimer structures may not
represent an authentic dimer interface that is formed by the C-
terminal domain of the intact HIV-1 p24 protein. In contrast, the
introduction of multiple mutations along the dimerization a-helix
and the flexible structural feature of p24 preclude a meaningful
interpretation of the p24 dimer interface that is observed in the
full-length p24 structures.
Our strategy to identify full-length p24 capsid proteins with
elevated dimerization affinities from wild HIV-1 strains should
overcome any experimental artifacts introduced by mutations or
truncations in p24 molecules. The discovery that the full-length
HIV-1 p24 capsid protein from the BMJ4 strain forms a stable
dimer in solution and in budding viruses in cultured cells provides
the unique opportunity for us to investigate the possible authentic
dimer interface of p24 (Fig. 3). The disulfide bond formed by
Cys177-Cys177 could reveal a potential physiological dimer
interface related to HIV-1 capsid assembly. The existence of such
novel shoulder-to-shoulder dimer trapped by S-S bridge is further
validated by mutational analysis of isolated p24 capsid proteins
and a mutated BMJ4 strain (Figs. 3C, 4F). Moreover, the
introduction of a Cys at residue 177 is able to the trigger the
p24 capsid protein in other HIV-1 strains to form a stable dimer in
solution, strongly suggesting that the involvement of residue 177 in
dimer formation could be relevant to HIV-1 capsid assembly
(Fig. 4D).
Our new strategy for p24 dimer screening has revealed a novel
shoulder-to-shoulder dimer, which is mediated by Cys177.
However, we speculate that Cys177 itself may not be critical for
HIV-1 replication since many other HIV-1 isolates lack this
unique Cys. Therefore, we prefer to argue that many dimer
structures could be existed during capsid assembly and this unique
Cys177 residue provides us an opportunity to discover the novel
shoulder-to-shoulder dimer interface. Although we lack direct
evidence demonstrating that the shoulder-to-shoulder dimer
interface is present in the mature HIV-1 capsid, we speculate
that such a dimer interface may be correlated with one of the
dimer interfaces associated with HIV-1 capsid assembly.
Materials and Methods
Plasmid and Strain Construction
The HIV-1 capsid CA genes (encoding p24) were generated by
commercial DNA synthesis or cloning from isolated HIV strains
representing various HIV subtypes, including A, B, B/C, C, D, D/
C, F and H subtypes. The genes amplified by PCR were first
cloned into the pMD 18-T vector using a TA cloning kit (Takara,
Dalian, China) and subsequently subcloned into the non-fusion
pTO-T7 vector with an additional N-terminal start Met for
expression. The ER2566 Escherichia coli strain was used for protein
expression. The proteins were named B92 (A), BNL (B), B24 (B),
B89.6 (B), BRF (B), B22 (B), BSG (B/C), P3P24 (B/C), BMJ4 (C),
B94 (C), B249 (D/C), B93 (F) and B90 (H). Alanine scanning
mutagenesis of p24 (BMJ4) was performed using site-directed PCR
and confirmed with DNA sequencing. The proviral plasmid
pBMJ4 construct carrying the C177A mutation was generated
using the QuikChangeH Lightning Site-Directed Mutagenesis Kit
(Agilent) and confirmed by DNA sequencing. The plasmid
carrying the C177A mutation was transfected into 293FT cells
for the propagation of HIV-BMJ4-C177A for infectivity evalua-
tion.
Protein Expression, Purification and Fab Preparation
Protein expression was induced with 0.4 mM isopropyl-b-d-
thiogalactopyranoside for 6 h at 25uC. After harvesting, the cells
were re-suspended in a buffer containing 50 mM Tris-HCl buffer,
pH 7.2, 10 mM EDTA, 300 mM sodium chloride and disrupted
by sonication. The supernatant was treated with ammonium
sulfate and allowed to precipitate at 4uC, and the p24 protein
precipitated at 28% ammonium sulfate saturation. The precipi-
tated p24 protein was re-suspended in 20 mM phosphate buffer,
pH 6.0, and further purified by cation-exchange chromatography
using CM-5PW (TOSOH, Tokyo, Japan). Monoclonal antibodies
were raised from the cross-immunization of p24 proteins from the
different HIV subtypes using a standard murine mAb preparation
protocol. The broad-spectrum antibodies were identified using the
cross-reaction criteria for all of the representative p24 proteins in
an ELISA (Figure S4).The A10F9 Fab fragment was obtained by
papain digestion of the purified A10F9 antibody followed by
anion-exchange chromatography using DEAE-5PW (TOSOH).
Purification and Crystallization of the p24:A10F9
Complex
The stable p24:A10F9 Fab complex was obtained by incubating
the two purified components (referred to Supporting Information)
with an excess of A10F9 Fab (molar ratio 1:1.5) at 37uC for 2 h
and further purification with G5000PW (TOSOH) in 20 mM
HEPES buffer at pH 7.0. The complex was concentrated to
,6 mg/ml for crystallization trials. Diffraction-quality crystals
were grown by equilibrating 1 ml of the p24:A10F9 complex
protein solution and 1 ml of the reservoir solution (0.2 M NaBr,
14% PEG 3350 and 0.2 M NaCl) using the hanging drop vapor
diffusion technique at 22uC. These crystals grew to a maximum
size of 0.3 mm60.1 mm60.05 mm over 2 weeks.
Structure Determination
Crystals were cryo-protected in the reservoir solution, which
was supplemented with 25–30% glycerol, and flash cooled at
100 K. The diffraction data from the p24:A10F9 crystals were
collected at the Shanghai Synchrotron Radiation Facility (SSRF)
beamline BL17U using a Quantum-315r CCD Area Detector. All
of the datasets were processed using the HKL-2000 program
package (www.hkl-xray.com). The structures of the BMJ4 p24
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dimer in complex with the A10F9 Fab fragment were determined
by molecular replacement using Fab 13B5 as the search model
(PDBID: 1E6J). The A10F9 Fab fragment part was built and
refined first, and the p24 dimer model was subsequently built after
several rounds of refinement on the A10F9 Fab model only. The
model was built using the O program (http://xray.bmc.uu.se/
alwyn) and refined using REFMAC/CCP4 (www.ccp4.ac.uk) with
the crystallographic statistics listed in Table 1. Our current
complex model includes two A10F9 Fab fragment copies and one
p24 CTD dimer (residues 149–221), and the p24 NTD is not
included in our final model due to the low quality of its density
map.
SDS-PAGE and Western Blotting (WB)
The analysis of proteins and HIV virions by SDS-PAGE was
performed according to the Laemmli method with minor
modifications. Polyacrylamide gels containing 12% acrylamide in
the separating gel and 5% acrylamide in the stacking gel were
used. Protein samples or heat-inactivated HIV samples were
mixed with equal volumes of 2x loading buffer (100 mM Tris-
HCl, pH 6.8, 200 mM BME, 4% SDS, 0.2% bromophenol blue
and 20% glycerol). Sample mixtures were heated at 100uC for
3 min and subsequently loaded in the separating gel. For the non-
reducing SDS gel, the buffer contained only 0.1% SDS (no BME),
and the sample was not boiled.
For Western blotting experiments, separated proteins were
transferred from an SDS gel onto a nitrocellulose membrane.
Membranes were soaked in monoclonal antibody (A10F9) diluted
1:2,000, incubated at room temperature for 1 h, and subsequently
washed with 0.2% Tween 20 in phosphate-buffered saline (at
pH 7.4). The bound antibody was detected with an alkaline
phosphatase-conjugated secondary antibody (DAKO, Glostrup,
Denmark), and developed using a mixture of nitro blue
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.
Analytical Ultra-centrifugation (AUC)
Sedimentation velocity (SV) was used to determine the
molecular weight of p24 in solution. All of the tested samples
were diluted to final concentration of 0.9 mg/ml (OD280 nm of
,1.0 in a 1.2 cm light path in phosphate-buffered saline (pH 7.4).
The experiments were conducted at 20uC on a Beckman XL-A
analytical ultracentrifuge, equipped with absorbance optics and an
An60-Ti rotor. The rotor speed was 45,000 rpm. The sedimen-
tation coefficient was obtained using the c(s) method [28] and then
scaled to c(M) profiles for MW calculation using Sedfit software,
which was kindly provided by Dr. P. Schuck, National Institutes of
Health (http://www.analyticalultracentrifugation.com).
Gel Filtration HPLC
Purified proteins were passed through a G5000PWxl GFC
column that was equilibrated in phosphate-buffered saline (at
pH 7.4) using an Agilent1200 HPLC (Agilent, Santa Clara, USA)
at a 0.5 ml/min flow rate. The UV absorbance at the 280 nm
wavelength was recorded during the elution.
ELISA
An enzyme-linked immunosorbent assay (ELISA) was per-
formed to evaluate the reactivity of the A10F9 mAb with various
p24 proteins and their mutants. Each well of a 96-well microplate
was coated with p24 protein (100 ng/well). The solid surface was
then incubated with two-fold serial dilutions of the A10F9 mAb at
37uC for 1 h, and the HRP-conjugated GAM secondary antibody
was added to the microplate for 30 min at 37uC. Subsequently,
100 ml of tetramethylbenzidine substrate was added, and the plates
were incubated for 10 min at 37uC. The reaction was stopped by
adding 50 ml 2 M H2SO4, and the OD was determined at 450 nm
and corrected against 620 nm. The EC50 (half maximal effective
concentration) value of A10F9 binding to p24 was calculated by
plotting the dose-response curve as the OD450 nm vs. the mAb
concentration. To quantify the HIV p24 protein, a double-
antibody sandwich ELISA was performed. The first antibody,
anti-p24 mAb 16G12, was coated onto a 96-well microplate. The
secondary antibody, anti-p24 mAb2F2, was labeled with HRP.
Two-fold serial dilutions of highly purified p24 proteins at 1,400,
700, 350, 175, and 87.5 pg/ml were used for reference standard
curve calibration. The p24 concentration in a sample of interest
could then be measured by the OD450 nm value determined by the
calibration curve.
Immunofluorescence Confocal Microscopy
To verify that A10F9 recognizes natural p24 in HIV, the pNL4-
3 or BMJ4 proviral DNA plasmid was transfected into 293FT cells
(105 cells/well, 24-well plate, with glass coverslips preset in the
wells) using Lipofectamine 2000 (Invitrogen, Carlsbad, USA). The
cells were then cultured for 48 h at 37uC. After washing in PBS,
the cells were fixed for 20 min at room temperature in 4%
paraformaldehyde (Sigma, St. Louis, USA), permeabilized with
0.3% Triton X-100 (Sigma) for 10 min, washed in PBS, and
incubated in goat serum for 1 h. The cells were stained with a
primary A10F9 mAb and a secondary goat anti-mouse antibody
that was coupled to FITC (Sigma). Nuclei were stained with DAPI
(Sigma). Confocal laser scanning microscopy was performed using
a Zeiss LSM 780 microscope (Carl Zeiss MicroImaging, Jena,
Germany).
BIAcore Biosensor Analysis
Gold-coated CM-5 sensor chips were coated with a carboxyl-
ated dextran polymer matrix in which the GAM-Fc (goat anti-
mouse antibody Fc fragment) was amine coupled. The affinity
measurement of A10F9 mAb binding to p24 (BMJ4) was initiated
by passing HBS over the sensor surface for 100 s at 10 ml/min,
and 30 ml of the A10F9 mAb was then injected at the same flow
rate. Subsequently, 50 ml of serially diluted p24 was injected. Five
concentrations were used for p24 (BMJ4): 2 nM, 4 nM, 10 nM,
20 nM, and 30 nM. Each measurement with the BIAcore3000
biosensor (GE Healthcare, Uppsala, Sweden) was repeated five
times, and the mean values were used for affinity constant fitting.
ELISpot Assay
The infectivity of the HIVMJ4 viruses containing Cys177 or
Ala177 was evaluated using an ELISpot assay. Briefly, the proviral
DNA plasmids pMJ4 and pMJ4-C177A were transfected into
293FT cells using Lipofectamine 2000 (Invitrogen). The propa-
gated HIV in the culture medium was harvested after 72 h and
quantified using the above-mentioned double-antibody sandwich
ELISA. Two concentrations (3 ng and 6 ng) of p24 from the
HIVMJ4 and HIVMJ4-C177A virus stocks were added to Tzm-bl cells
in a 96-well plate. HIV infections were performed in the presence
or absence of 15 mg/ml DEAE/dextran for 40 h at 37uC. Tzm-bl
cells were fixed in glutaraldehyde (0.2%) and stained with an X-gal
substrate. HIV-infected cell spots were counted using an Immuno-
spot Series Analyzer (Cellular Technology, Cleveland, USA).
Average and standard error of five-time repeats of counts on
ELISpot were plotted in histogram form. P-value analysis was used
to evaluate the signficant change of the infectivity of C177A
mutation vs. prototype BMJ4.
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Accession Numbers
Coordinates have been deposited in the Protein Data Bank
(accession code 3VRL).
Supporting Information
Figure S1 The A10F9 monoclonal antibody displays
higher binding affinity to BMJ4 p24. (A) EC50 calculation
of various p24 proteins binding with the A10F9 mAb. The
OD450 nm vs. A10F9 concentration ELISA curves were fitted to a
half point of effective concentration (EC50), and the value is shown
in brackets. (B) The binding affinity constant of the A10F9
monoclonal antibody with the BMJ4 p24 proteins was measured
with a Biacore biosensor assay. (C) A10F9 binding with native
HIV in immunofluorescence images. The DAPI-stained nucleus is
shown in blue, and A10F9 mAbs recognizing pNL4-3 or BMJ4
p24 was visualized by a FITC-labeled goat anti-mouse antibody in
green.
(TIF)
Figure S2 Gel filtration purification of BMJ4 p24
protein in complex with A10F9 Fab. The purification was
performed in Agilent1200 HPLC system with G5000PWXL
column. The major peak demonstrating as bigger size with respect
to the peak of excess A10F9 Fab was collected for concentrating
and crystallization. Dark green, the analysis of individual BMJ4
p24; Cyan, the analysis of individual A10F9 Fab; Magenta, the
resultant chromatography profile of the purification of the BMJ4-
A10F9 complex.
(TIF)
Figure S3 A10F9 monoclonal antibody displays binding
ability to BMJ4 p24 CTD. (A) The C-terminal domain (CTD)
of BMJ4 p42 resolves as dimer in non-reducing condition but
dissociates to monomer with DTT treat, which is consistent with
the full-length BML4 p24 protein. (B) A10F9 monoclonal antibody
displays binding ability to BMJ4CTD instead of BMJ4NTD. 1,
BMJ4NTD-reducing; 2, BMJ4NTD-nonreducing; 3, Protein MW
Marker; 4, BMJ4CTD-reducing; 5, BMJ4CTD-nonreducing.
(TIF)
Figure S4 A selected antibody panel against the HIV p24
capsid protein. (A) Broad-spectrum anti-p24 antibodies were
characterized by various p24 binding tests. (B) The anti-p24
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